[go: up one dir, main page]

NO20061340L - Anvendelse av fumarsyrederivater for behandling av hjerteinsuffisiens og astma - Google Patents

Anvendelse av fumarsyrederivater for behandling av hjerteinsuffisiens og astma

Info

Publication number
NO20061340L
NO20061340L NO20061340A NO20061340A NO20061340L NO 20061340 L NO20061340 L NO 20061340L NO 20061340 A NO20061340 A NO 20061340A NO 20061340 A NO20061340 A NO 20061340A NO 20061340 L NO20061340 L NO 20061340L
Authority
NO
Norway
Prior art keywords
fumaric acid
asthma
fumarates
monoalkyl
monoamido
Prior art date
Application number
NO20061340A
Other languages
English (en)
Other versions
NO335991B1 (no
Inventor
Rajendra Kumar Joshi
Hans-Peter Strebel
Christian Zaugg
Michael Tamm
Original Assignee
Fumapharm Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10360869A external-priority patent/DE10360869A1/de
Application filed by Fumapharm Ag filed Critical Fumapharm Ag
Publication of NO20061340L publication Critical patent/NO20061340L/no
Publication of NO335991B1 publication Critical patent/NO335991B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

I følge et første trekk omhandler oppfinnelsen anvendelse av fumarsyrederivater valgt fra gruppen omfattende dialkylfumarater, monoalkylhydrogenfumarater, fumarsyremonoalkylestersalter, fumarsyremonoamider, monoamidofumarsyresalter, fumarsyrediamider, monoalkylmonoamidofumarater, karbosykliske og oksakarbosykliske oligomerer av disse forbindelsene samt blandinger derav for fremstilling av et medikament for behandling av kardiologisk insuffisiens, spesielt ventrikulær insuffisiens, myokardial infarkt og angina pektoris. I følge et andre trekk omhandler oppfinnelsen anvendelse av fumarsyrederivater valgt fra gruppen omfattende dialkylfumarater, monoalkylhydrogenfumarater, fumarsyremonoalkylestersalter, fumarsyremonoamid, fumarsyresalter, fumarsyrediamider, monoalkylmonoamidofumarater, karbosykliske og oksakarbosykliske oligomerer av disse forbindelsene samt blandinger derav for fermstilling av et medikament for behandling av astma og kronisk obstruktive pulmonale sykdommer, spesielt astma forårsaket av allergier, infeksjoner, analgetika, arbeidsbetingelser eller fysisk anstrengelse, blandete former for astma eller astma kardiale.
NO20061340A 2003-09-09 2006-03-24 Anvendelser av et fumarsyrederivat for fremstilling av et medikament for behandling eller hindring av kardiologisk insuffisiens NO335991B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10341530 2003-09-09
DE10360869A DE10360869A1 (de) 2003-09-09 2003-12-23 Verwendung von Fumarsäurederivaten zur Therapie der Herzinsuffizienz, der Hyperkeratose und von Asthma
PCT/EP2004/009835 WO2005023241A1 (en) 2003-09-09 2004-09-03 The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma

Publications (2)

Publication Number Publication Date
NO20061340L true NO20061340L (no) 2006-03-24
NO335991B1 NO335991B1 (no) 2015-04-13

Family

ID=34276548

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061340A NO335991B1 (no) 2003-09-09 2006-03-24 Anvendelser av et fumarsyrederivat for fremstilling av et medikament for behandling eller hindring av kardiologisk insuffisiens

Country Status (15)

Country Link
US (3) US20070027076A1 (no)
EP (2) EP1913942B1 (no)
AT (1) ATE380027T1 (no)
AU (1) AU2004269903B2 (no)
BR (1) BRPI0410805A (no)
CA (1) CA2526586C (no)
DE (1) DE602004010531T2 (no)
DK (1) DK1663197T3 (no)
ES (1) ES2297461T3 (no)
MX (1) MXPA06002657A (no)
NO (1) NO335991B1 (no)
PL (1) PL1663197T3 (no)
RU (1) RU2313339C2 (no)
SI (1) SI1663197T1 (no)
WO (1) WO2005023241A1 (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
EE05472B1 (et) 2001-01-12 2011-10-17 Fumapharm Ag Fumaarhappeamiidide kasutamine ravimina
WO2005023241A1 (en) 2003-09-09 2005-03-17 Fumapharm Ag The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
DK1799196T3 (en) * 2004-10-08 2016-08-15 Forward Pharma As Controlled release pharmaceutical compositions comprising a fumaric acid ester
TWI405756B (zh) 2005-12-21 2013-08-21 Array Biopharma Inc 新穎硫酸氫鹽
LT2653873T (lt) 2007-02-08 2022-10-10 Biogen Ma Inc. Kompozicijos ir naudojimas, skirti išsėtinei sklerozei gydyti
US20100130607A1 (en) * 2007-02-08 2010-05-27 Ralf Gold Neuroprotection in demyelinating diseases
DE102008030023A1 (de) 2008-06-16 2009-12-17 Eberhard-Karls-Universität Tübingen Universitätsklinikum Arzneimittel zur Behandlung einer durch Parasiten verursachten Krankheit
RU2383345C1 (ru) * 2008-08-07 2010-03-10 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") Способ лечения больных бронхиальной астмой
EP2334378B1 (en) 2008-08-19 2014-04-09 XenoPort, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
CN109044985A (zh) 2009-01-09 2018-12-21 前进制药知识产权有限公司 包含溶蚀骨架中的一种或多种富马酸酯的药物制剂
WO2012097011A1 (en) * 2011-01-10 2012-07-19 Sorbent Therapeutics, Inc. Compositions comprising crosslinked cation- binding polymers and a base, uses thereof
US9422226B2 (en) 2011-06-08 2016-08-23 Biogen Ma Inc. Process for preparing high purity and crystalline dimethyl fumarate
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
MX2014009511A (es) 2012-02-07 2014-10-24 Xenoport Inc Compuestos de fumarato de morfolinoalquilo, composiciones farmaceuticas y metodos de uso.
MX370785B (es) 2012-02-07 2020-01-06 Biogen Ma Inc Composiciones farmacéuticas que contienen fumarato de dimetilo.
AU2013305684B2 (en) 2012-08-22 2016-11-24 Xenoport, Inc. Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
JP2015527372A (ja) 2012-08-22 2015-09-17 ゼノポート，インコーポレイティド 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法
WO2014071371A1 (en) 2012-11-05 2014-05-08 Xenoport, Inc. Cocrystals of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate
AR094277A1 (es) 2012-12-21 2015-07-22 Biogen Idec Inc Derivados de fumarato sustituidos con deuterio
PT2970101T (pt) 2013-03-14 2018-10-04 Alkermes Pharma Ireland Ltd Pró-fármacos de fumaratos e seu uso no tratamento de várias doenças
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
WO2014160633A1 (en) * 2013-03-24 2014-10-02 Xenoport, Inc. Pharmaceutical compositions of dimethyl fumarate
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
EP3041467A1 (en) 2013-09-06 2016-07-13 XenoPort, Inc. Crystalline forms of (n,n-diethylcarbamoyl)methyl methyl (2e)but-2-ene-1,4-dioate, methods of synthesis and use
WO2015042294A1 (en) 2013-09-18 2015-03-26 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
EP3110793B1 (en) 2014-02-24 2019-08-21 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
WO2015130998A1 (en) 2014-02-28 2015-09-03 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016061393A1 (en) 2014-10-15 2016-04-21 Xenoport, Inc. Fumarate compounds, pharmaceutical compositions, and methods of use
WO2016074684A1 (en) * 2014-11-11 2016-05-19 Syddansk Universitet Fumaric acid derivatives for medical use
EP3253377B1 (en) 2015-02-08 2021-05-12 Alkermes Pharma Ireland Limited Monomethylfumarate prodrug compositions
MA41785A (fr) * 2015-03-20 2018-01-23 Biogen Ma Inc Procédés et compositions pour l'administration intraveineuse de fumarates pour le traitement de maladies neurologiques
DK3273951T3 (da) 2015-03-27 2020-11-02 Symbionyx Pharmaceuticals Inc Sammensætninger og fremgangsmåder til behandling af psoriasis
CA2987895A1 (en) * 2015-06-01 2016-12-08 Sun Pharmaceutical Industries Ltd. Pharmaceutical compositions of dimethyl fumarate
US10213411B2 (en) * 2015-08-27 2019-02-26 Vijaykumar Rajasekhar Use of prodrugs of fumarates in treating heart failure diseases
WO2017060400A1 (en) 2015-10-07 2017-04-13 Neurovive Pharmaceutical Ab Protected carboxylic acid-based metabolites for the treatment of disesases related to mitochondrial dysfunctions
DE102015117882A1 (de) 2015-10-21 2017-04-27 Mehrdad Ghashghaeinia Pharmazeutische Zusammensetzung
US9993265B2 (en) * 2015-12-01 2018-06-12 Lsi Solutions, Inc. Percuscopic access device and cleaning obturator
US10463642B2 (en) * 2016-02-01 2019-11-05 Vijaykumar Rajasekhar Methods of treating heart failure diseases using prodrugs of methyl hydrogen fumarate
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
CN118903149A (zh) * 2024-07-19 2024-11-08 文韬创新药物研究(北京)股份有限公司 含泼尼松的药物组合物及其制备方法和应用

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1153927A (en) 1966-08-25 1969-06-04 Wilhelm Hoerrmann Medicinal Composition Suitable For Treating Diseases Of The Retina
GB1357813A (en) * 1970-09-07 1974-06-26 Siphar Sa Effervescent composition for the treatment of heart diseases
DE2530372A1 (de) 1975-07-08 1977-01-13 Walter Dr Schweckendiek Pharmazeutische zubereitungen zur behandlung von psoriasis
JPS5283957A (en) 1975-12-01 1977-07-13 Henkel & Cie Gmbh Medicine for treating metabolic obstruction of calcium
DK506476A (da) * 1975-12-01 1977-06-02 Henkel & Cie Gmbh Farmaceutiske preparater til behandling af calciumstofs skifteforstyrrelser
DE2621214C3 (de) 1976-05-13 1981-11-12 Koronis Gmbh Chemisch-Pharmazeutische Praeparate, 5441 Sassen Verwendung von Stabilisatoren in Arzneimitteln mit Fumarsäuremonoäthylester und desen Mineralsalzen
JPS5824104B2 (ja) 1977-12-06 1983-05-19 博衛 小川 フマル酸製剤
DE2840498C2 (de) 1978-09-18 1980-04-10 Walter Dr. 6700 Ludwigshafen Schweckendiek Pharmazeutische Zubereitungen zur Behandlung von Psoriasis
DE3127432A1 (de) * 1981-07-11 1983-02-03 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von fumarsaeuremonoester
DE3233830A1 (de) 1982-09-11 1984-03-15 Hoechst Ag, 6230 Frankfurt Perfluoralkyl-malein- und -fumarsaeureamide, verfahren zu deren herstellung und ihre verwendung als schmutzabweisendes mittel
CH664150A5 (de) * 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
US5149695A (en) * 1985-01-15 1992-09-22 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
JPS61194020A (ja) * 1985-02-22 1986-08-28 Dai Ichi Seiyaku Co Ltd 網膜症治療剤
GB2176999B (en) 1985-06-22 1989-07-12 Stanley Stewart Davis Sustained release medicament
US4855305A (en) 1987-03-23 1989-08-08 Applied Medical Research Compositions and methods of effecting contraception utilizing melatonin
IL83775A (en) 1987-09-04 1991-12-15 Dexter Chemical Corp Amino acid esters and amides of fumaric acid and pharmaceutical compositions containing them for use in the treatment of psoriasis
US5214196A (en) * 1987-09-04 1993-05-25 Dexter Chemical Corporation Diethyl ester of di-glycyl fumaramide
US5242905A (en) * 1987-09-04 1993-09-07 Dexter Chemical Corporation Pharmaceutical compositions for the treatment of psoriasis
US5424332A (en) * 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
DE3834794A1 (de) 1988-10-12 1990-04-19 F Schielein Oral zu verabreichendes mittel zur behandlung von psoriasis
ATE194835T1 (de) * 1990-04-25 2000-08-15 Nissan Chemical Ind Ltd Pyridazinonderivat
DE4014252A1 (de) * 1990-05-04 1991-11-07 Boehringer Ingelheim Vetmed Enantiomerentrennung von cimaterol, (-)-cimaterol und dessen verwendung als arzneimittel oder als leistungsfoerderer
US5484610A (en) * 1991-01-02 1996-01-16 Macromed, Inc. pH and temperature sensitive terpolymers for oral drug delivery
AU1271592A (en) * 1991-01-18 1992-08-27 Dexter Chemical Corporation Malic acid derivatives and compositions for the treatment of psoriasis
IT1251166B (it) 1991-08-09 1995-05-04 Chiesi Farma Spa Derivati di geneserina,loro preparazione e composizioni farmaceutiche che li contengono
FR2694693B1 (fr) 1992-07-28 1994-10-28 Abrax Bio Labs Sa Composition pharmaceutique à base de flavopéréirine et son utilisation dans un traitement contre le virus VIH.
US5434185A (en) 1993-05-17 1995-07-18 The University Of Kentucky Research Foundation Method for inhibiting angiogenesis with aurintricarboxylic acid, its analogues or salts
GB2294637B (en) 1993-06-08 1997-11-12 Raymond K Brown Therapeutic compositions and methods of use
JPH06345644A (ja) 1993-06-10 1994-12-20 Unitika Ltd 自己免疫性疾患治療剤
CA2125763C (en) * 1993-07-02 2007-08-28 Maurice Kent Gately P40 homodimer of interleukin-12
ATE177420T1 (de) 1993-11-04 1999-03-15 Abbott Lab Cyclobutan-derivate als inhibitoren der squalen- synthetase und der protein-farnesyltransferase
US5407772A (en) * 1993-11-30 1995-04-18 Xerox Corporation Unsaturated polyesters
DK0750616T3 (da) 1994-03-16 2001-07-23 Cenes Ltd Syreadditionssalte af 2,3,4,5-tetrahydro-1H-3-benzazapinforbindelser
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
GB2291422A (en) 1994-07-18 1996-01-24 Fujisawa Pharmaceutical Co 4-phenyl-pyrido[2,3-b]pyrazin-4-ones
US5763190A (en) 1994-09-21 1998-06-09 The Trustees Of The University Of Pennsylvania Methods for the identification of compounds capable of inducing the nuclear translocation of a receptor complex comprising the glucocoticoid receptor type II and viral protein R interacting protein
CN1125141A (zh) 1994-12-22 1996-06-26 杭州中美华东制药有限公司 一种含环孢菌素a的固体分散物及其外用剂型上的用途
JP2535141B2 (ja) 1995-01-17 1996-09-18 中外製薬株式会社 フマル酸含有徐放性製剤
US6011000A (en) * 1995-03-03 2000-01-04 Perrine; Susan P. Compositions for the treatment of blood disorders
WO1997009984A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Immunosuppressant
EP0852233A4 (en) 1995-09-21 1999-09-15 Nippon Shinyaku Co Ltd CYCLOSPORIN PHOSPHATE DERIVATIVES AND MEDICINAL COMPOSITION
HU9502843D0 (en) 1995-09-29 1995-11-28 Livigene Ltd Pharmaceutical composition
JP4004567B2 (ja) 1996-02-14 2007-11-07 アステラス製薬株式会社 Ｗｂ２６６３ｂ物質を含有する免疫抑制剤
KR970064620A (ko) 1996-03-05 1997-10-13 임성기 사이클로스포린-함유 외용약제 조성물
NZ333456A (en) 1996-05-22 2000-08-25 Univ Alberta Type-2 chemokine binding proteins and methods of use therefor
WO1997048405A1 (fr) 1996-06-21 1997-12-24 Jury Evgenievich Belyaev Produit semi-fini permettant d'obtenir des bases de medicaments, bases de medicaments obtenues a l'aide ce dernier et variantes, et medicament faisant appel a ces bases et variantes
EP1886677A1 (en) 1996-07-26 2008-02-13 Susan P. Perrine Use of an inducing agent for the treatment of blood, viral and cellular disorders
AU5474198A (en) 1996-12-24 1998-07-17 National Research Council Of Canada Treatment of diseases or prevention of cellular damage caused by oxygen-containing free radicals
US5972363A (en) * 1997-04-11 1999-10-26 Rohm And Haas Company Use of an encapsulated bioactive composition
DE19721099C2 (de) * 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
ATE555780T1 (de) 1997-10-24 2012-05-15 John P Blass Nahrungsergänzungsmittel für metabolische hirnleistungsstörungen
US20050245612A1 (en) 2004-05-03 2005-11-03 Blass John P Pharmaceutical compositions for metabolic insufficiencies
EP1051159B1 (en) 1998-01-22 2002-04-10 Zentaris AG Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis
DE19814358C2 (de) * 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) * 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) * 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) * 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US6537584B1 (en) * 1999-11-12 2003-03-25 Macromed, Inc. Polymer blends that swell in an acidic environment and deswell in a basic environment
DE10000577A1 (de) * 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
WO2001059072A1 (en) 2000-02-11 2001-08-16 Philadelphia Health And Education Corporation Differentiation of bone marrow cells into neuronal cells and uses therefor
WO2002002190A2 (en) 2000-07-05 2002-01-10 Johns Hopkins School Of Medicine Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
WO2002024144A2 (en) * 2000-09-20 2002-03-28 Beth Israel Deaconness Medical Center Use of transcription factors for treating inflammation and other diseases
JP2002148784A (ja) * 2000-11-07 2002-05-22 Tokyo Ohka Kogyo Co Ltd 化学増幅型ポジ型レジスト塗布液及びそれを用いたレジストパターン形成方法
WO2002038141A2 (en) 2000-11-08 2002-05-16 Massachusetts Institute Of Technology Compositions and methods for treatment of mild cognitive impairment
DE10101307A1 (de) 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
EE05472B1 (et) * 2001-01-12 2011-10-17 Fumapharm Ag Fumaarhappeamiidide kasutamine ravimina
UA76444C2 (en) * 2001-02-14 2006-08-15 Composition of biochemical compounds involved in bioenergy metabolism of cells and method of its use in prevention and therapy of diseases
RU2189813C1 (ru) 2001-06-01 2002-09-27 Российский научно-исследовательский институт гематологии и трансфузиологии Лекарственное средство антигипоксического действия
RU2330642C2 (ru) 2001-07-06 2008-08-10 Лайфсайкл Фарма А/С Регулируемая агломерация
US20030104997A1 (en) * 2001-09-05 2003-06-05 Black Ira B. Multi-lineage directed induction of bone marrow stromal cell differentiation
CA2463624A1 (en) 2001-10-15 2003-04-24 National Research Council Of Canada Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
ES2399880T3 (es) 2002-03-15 2013-04-04 Cypress Bioscience, Inc. Milnaciprán para el tratamiento del síndrome del intestino irritable
DE10214031A1 (de) 2002-03-27 2004-02-19 Pharmatech Gmbh Verfahren zur Herstellung und Anwendung von Mikro- und Nanoteilchen durch aufbauende Mikronisation
DE10217314A1 (de) * 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
CA2481934A1 (en) 2002-04-18 2003-10-30 Pharmacia Corporation Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
US6830759B2 (en) * 2002-06-28 2004-12-14 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
SI1575565T1 (sl) 2003-08-08 2010-04-30 Biovail Lab Int Srl Tableta bupropion hidroklorida z modificiranim sprošŽŤanjem
WO2005023241A1 (en) 2003-09-09 2005-03-17 Fumapharm Ag The use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
DE10342423A1 (de) 2003-09-13 2005-04-14 Heidland, August, Prof. Dr.med. Dr.h.c. Verwendung von Fumarsäurederivaten zur Prophylaxe und zur Behandlung von Genomschäden
KR20070007868A (ko) 2004-03-31 2007-01-16 비피에스아이 홀딩스, 인코포레이션. 경구 섭취 가능한 기질용 장용성 피복
DK1799196T3 (en) 2004-10-08 2016-08-15 Forward Pharma As Controlled release pharmaceutical compositions comprising a fumaric acid ester
WO2006050730A1 (en) 2004-11-10 2006-05-18 Aditech Pharma Ab Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
EP1827491A4 (en) 2004-11-19 2010-07-14 Biogen Idec Inc TREATMENT OF MULTIPLE SCLEROSIS
US7638119B2 (en) 2004-12-02 2009-12-29 Wisconsin Alumni Research Foundation Method of diminishing the symptoms of neurodegenerative disease
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
US7566718B2 (en) 2005-02-16 2009-07-28 Schering Corporation Amine-linked pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
CA2598456A1 (en) 2005-02-16 2006-08-24 Schering Corporation Heterocyclic substituted piperazines with cxcr3 antagonist activity
CN101146793A (zh) * 2005-02-16 2008-03-19 先灵公司 具有cxcr3拮抗剂活性的新的杂环取代了的吡啶或苯基化合物
AU2006214378A1 (en) 2005-02-16 2006-08-24 Pharmacopeia, Inc. Pyridyl and phenyl substituted piperazine-piperidines with CXCR3 antagonist activity
CA2598489A1 (en) 2005-02-16 2006-08-24 Schering Corporation Piperazine-piperidines with cxcr3 antagonist activity
AU2006214380A1 (en) 2005-02-16 2006-08-24 Pharmacopeia, Inc. Pyrazinyl substituted piperazine-piperidines with CXCR3 antagonist activity
KR20070107040A (ko) 2005-02-16 2007-11-06 쉐링 코포레이션 Ｃｘｃｒ3 길항제 활성을 갖는 헤테로아릴-치환된피라지닐-피페라진-피페리딘
DE102005022845A1 (de) * 2005-05-18 2006-11-23 Fumapharm Ag Thiobernsteinsäurederivate und deren Verwendung
EP1959969A2 (en) 2005-07-01 2008-08-27 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
WO2007006308A1 (en) 2005-07-07 2007-01-18 Aditech Pharma Ab Novel glucopyranose esters and glucofuranose esters of alkyl- fu marates and their pharmaceutical use
WO2007006307A2 (en) 2005-07-07 2007-01-18 Aditech Pharma Ab Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
EP1940382A2 (en) 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
WO2007042034A1 (en) 2005-10-07 2007-04-19 Aditech Pharma Ab Controlled release pharmaceutical compositions comprising a fumaric acid ester
US20080089861A1 (en) 2006-07-10 2008-04-17 Went Gregory T Combination therapy for treatment of demyelinating conditions
KR20090047499A (ko) 2006-09-01 2009-05-12 씨브이 쎄러퓨틱스, 인코포레이티드 심근 조영법 동안에 환자의 순응성을 증가시키기 위한 방법및 조성물
US20100130607A1 (en) 2007-02-08 2010-05-27 Ralf Gold Neuroprotection in demyelinating diseases
LT2653873T (lt) 2007-02-08 2022-10-10 Biogen Ma Inc. Kompozicijos ir naudojimas, skirti išsėtinei sklerozei gydyti
US20080274182A1 (en) 2007-05-03 2008-11-06 Regina Helena Alida Boekema Tablet coatings made from modified carboxymethylcellulose materials
US20100093611A1 (en) 2007-05-16 2010-04-15 Horrigan Stephen K Compounds and methods for treating or preventing autoimmune diseases
EP2334378B1 (en) 2008-08-19 2014-04-09 XenoPort, Inc. Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
CN109044985A (zh) 2009-01-09 2018-12-21 前进制药知识产权有限公司 包含溶蚀骨架中的一种或多种富马酸酯的药物制剂
EP3466420A1 (en) 2009-04-29 2019-04-10 Biogen MA Inc. Dimethyl fumarate for the treatment of friedreich ataxia
DK2533634T3 (en) 2010-02-12 2016-01-25 Biogen Ma Inc NEURO PROTECTIVE demyelinating diseases
SG195049A1 (en) 2011-05-26 2013-12-30 Biogen Idec Inc Methods of treating multiple sclerosis and preserving and/or increasing myelin content
US9422226B2 (en) 2011-06-08 2016-08-23 Biogen Ma Inc. Process for preparing high purity and crystalline dimethyl fumarate
EP2791181A4 (en) 2011-12-16 2015-08-05 Biogen Ma Inc SILICONE-CONTAINING FUMIC ACID ESTERS
MX370785B (es) * 2012-02-07 2020-01-06 Biogen Ma Inc Composiciones farmacéuticas que contienen fumarato de dimetilo.
GB201208850D0 (en) 2012-05-18 2012-07-04 Alphaptose Gmbh Tri-subsituted glycerol compounds for use in the treatment of clinically isolated syndrome and/or multiple sclerosis

Also Published As

Publication number Publication date
SI1663197T1 (sl) 2008-06-30
EP1663197A1 (en) 2006-06-07
EP1913942B1 (en) 2009-11-11
DE602004010531T2 (de) 2008-07-03
US20110124615A1 (en) 2011-05-26
DK1663197T3 (da) 2008-01-07
US20070027076A1 (en) 2007-02-01
EP1913942A3 (en) 2008-05-21
EP1663197B1 (en) 2007-12-05
EP1913942A2 (en) 2008-04-23
US20160030374A1 (en) 2016-02-04
WO2005023241A1 (en) 2005-03-17
US8980832B2 (en) 2015-03-17
ATE380027T1 (de) 2007-12-15
ES2297461T3 (es) 2008-05-01
DE602004010531D1 (de) 2008-01-17
CA2526586A1 (en) 2005-03-17
RU2313339C2 (ru) 2007-12-27
CA2526586C (en) 2010-03-16
AU2004269903A1 (en) 2005-03-17
RU2005141547A (ru) 2006-06-10
MXPA06002657A (es) 2006-06-05
NO335991B1 (no) 2015-04-13
BRPI0410805A (pt) 2006-06-27
PL1663197T3 (pl) 2008-09-30
AU2004269903B2 (en) 2010-09-02

Similar Documents

Publication Publication Date Title
NO20061340L (no) Anvendelse av fumarsyrederivater for behandling av hjerteinsuffisiens og astma
NO20082000L (no) Pyrimidinamidforbindelser som PGDS-inhibitorer
NO20072153L (no) (Bifenyl)-karboksylsyrer og derivater derav
SE0200356D0 (sv) Novel use
EA201100423A1 (ru) Новые бензамиды, их получение и их применение в качестве лекарственных средств
MY165906A (en) Phenothiazine diaminium salts and their use
IL184125A (en) Use of 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)- methylcarbonyl)-n-methyl-amino)-anilino)-1-phenyl-methylene]-6 methoxycarbonyl-2-indolinone for the preparation of a medicaments for the prevention or treatment of idiopathic pulmonary fibrosis
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
ECSP10010336A (es) Derivados de piridina
NO20052802L (no) Pyrrolopyrimidinderivativer
NO20082498L (no) Diarylurea for behandling av pulmonar hypertensjon
CY1115940T1 (el) Παραγωγα υποκατεστημενου φαινυλαλκανοϊκου οξεος και η χρηση τους για τη θεραπευτικη αντιμετωπιση αναπνευστικων ασθενειων
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
NO20070458L (no) Aryl-pyridinderivater som 11-Beta-HSD1 inhibitorer
CA2534571A1 (en) Substituted isoquinoline derivatives and methods of use
NO20090328L (no) Nye forbindelser 385
ATE311380T1 (de) Durch säuregruppen disubstitierte heteroaryl- derivate und ihre verwendung als matrix metalloproteinas inhibitoren
UA82980C2 (ru) Замещенные амиды бензойной кислоты и их применение для угнетения ангиогенеза
ATE440834T1 (de) Substituierte arylaminderivate und verwendungsverfahren
DK2032534T3 (da) 4-[(3-fluorphenoxy)phenylmethyl]piperidinmethansulfonat: anvendelser, fremgangsmåder til syntese og farmaceutiske præparater
IL169257A0 (en) Cycloalkene dicarboxylic acid compounds as anti-infammatory, immunomodulatory and anti-proliferatory agents
CO6270318A2 (es) Acido 4-[4-(2adamantilcarbomoil)-5-tert-butilpirazol -1-il]benzoico-465
Vaccaro et al. Dihydropyrazolopyrimidine Inhibitors of KV1. 5 (IKur)
DE602004015788D1 (de) Verwendung von Phenylbenzamide-derivaten zur Behandlung von chronisch-obstruktiver Lungenerkrankung (COPD)
ES2249488T3 (es) Moduladores de canales de sodio derivados de 2-piperidilimidazoles.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees